Table 3.

Major adverse cardiac events (MACE) for long term versus short term dual antiplatelet therapy (DAPT) after implantation of drug eluting stent in subgroups of patients with or without diabetes

	Diabetes (n=3681)					No diabetes (n=7708)				P for interaction for diabetes/DAPT
	HR (95% CI)	P value	τ2	P for interaction		HR (95% CI)	P value	τ2	P for interaction
Age (years):
<65	1.26 (0.33 to 4.77)	0.74	1.87	0.84		0.84 (0.52 to 1.34)	0.46	0.04	0.50	0.58
≥65	1.09 (0.68 to 1.76)	0.71	0.00			1.05 (0.68 to 1.63)	0.82	0.05		0.91
Sex:
Women	1.32 (0.78 to 2.21)	0.30	0.03	0.09		1.25 (0.65 to 2.37)	0.50	0.14	0.20	0.90
Men	0.67 (0.38 to 1.21)	0.90	0.08			0.77 (0.55 to 1.10)	0.15	0.00		0.69
Clinical presentation:
Stable CAD	1.10 (0.63 to 1.92)	0.74	0.09	0.84		1.21 (0.79 to 1.85)	0.38	0.03	0.20	0.79
ACS	0.98 (0.37 to 2.58)	0.97	0.83			0.76 (0.43 to 1.33)	0.34	0.16		0.66
Multivessel disease:
No	1.74 (0.91 to 3.32)	0.09	0.17	0.09		1.27 (0.82 to 1.96)	0.28	0.06	0.12	0.43
Yes	0.75 (0.36 to 1.57)	0.44	0.38			0.69 (0.37 to 1.28)	0.24	0.20		0.87

ACS=acute coronary syndrome; CAD=coronary artery disease.